A major challenge to the adoption of personalized medicine approaches to diagnosis and treatment, using genomic information, is that the data required to address critical questions relevant to clinical applications, economics, policy, and regulatory issues are widely dispersed. An immediate concern is to identify the personalized medicine approaches that are now being used in clinical practice or are in advanced stages of development, and then to evaluate how those approaches came to be adopted, their apparent value to date, and what their impact has been. We have been developing and piloting a framework for the collection and synthesis of data related to personalized medicine with the goal of establishing an evidence base on technologies and research for translating research findings into clinical practice and policy. The Evidence Project will build on our pilot work with an emphasis on personalized medicine for colorectal and breast cancer. Our objective is to develop an evidence base on personalized medicine technologies, using genomics, for colorectal and breast cancer.
The Specific Aims are to:
Aim 1 : Identify, describe, and assess available data sources for the evidence base on colorectal and breast cancer personalized medicine interventions.
Aim 2 : Conduct case studies of personalized medicine technologies for colorectal and breast cancer that focus on clinical applications, economics, policy and regulatory issues and provide findings on key technologies and supplement detailed case studies with ongoing horizon scans of personalized medicine technology.
Aim 3 : Systematically review data needed for Program Projects: evaluations of clinical applications, including utilization data and studies of patients'and providers'preferences, and economic evaluations of personalized medicine Aim 4: Evaluate the policy implications of findings, including: what is known about personalized medicine innovations;how and why personalized medicine innovations get (or not get) to be adopted;and the potential or actual value and societal impact of personalized medicine innovations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA130818-02
Application #
7925766
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2009-09-01
Budget End
2010-08-31
Support Year
2
Fiscal Year
2009
Total Cost
$61,245
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Phillips, Kathryn A; Deverka, Patricia A; Sox, Harold C et al. (2017) Making genomic medicine evidence-based and patient-centered: a structured review and landscape analysis of comparative effectiveness research. Genet Med 19:1081-1091
Knight, Sara J; Mohamed, Ateesha F; Marshall, Deborah A et al. (2015) Value of Genetic Testing for Hereditary Colorectal Cancer in a Probability-Based US Online Sample. Med Decis Making :
Ponce, Ninez A; Ko, Michelle; Liang, Su-Ying et al. (2015) Early diffusion of gene expression profiling in breast cancer patients associated with areas of high income inequality. Health Aff (Millwood) 34:609-15
Phillips, Kathryn A; Labno, Anna (2014) Private Companies Providing Health Care Price Data: Who Are They and What Information do They Provide? J Manag Care Med 17:75-80
Pletcher, Mark J; Pignone, Michael; Earnshaw, Stephanie et al. (2014) Using the coronary artery calcium score to guide statin therapy: a cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes 7:276-84
Kilambi, Vikram; Johnson, F Reed; González, Juan Marcos et al. (2014) Valuations of genetic test information for treatable conditions: the case of colorectal cancer screening. Value Health 17:838-45
Phillips, Kathryn A; Ann Sakowski, Julie; Trosman, Julia et al. (2014) The economic value of personalized medicine tests: what we know and what we need to know. Genet Med 16:251-7
Ferrusi, Ilia L; Earle, Craig C; Trudeau, Maureen et al. (2013) Closing the personalized medicine information gap: HER2 test documentation practice. Am J Manag Care 19:838-44
Kuppermann, Miriam; Wang, Grace; Wong, Shirley et al. (2013) Preferences for outcomes associated with decisions to undergo or forgo genetic testing for Lynch syndrome. Cancer 119:215-25
Weitzel, Jeffrey N; Clague, Jessica; Martir-Negron, Arelis et al. (2013) Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network. J Clin Oncol 31:210-6

Showing the most recent 10 out of 43 publications